Decision-making at Swissmedic, the Swiss regulatory agency, with a focus on (neo)adjuvant cancer treatments

CONCLUSION: Approval and consensus decision rates at SMC in comparison to EMA and FDA were lower for (neo)adjuvant indications but not for advanced and metastastic NAS oncology indications.PMID:38442691 | DOI:10.1159/000536541

Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Matea Pavic Qiyu Li Stephanie Juritz Arunas Gircys Anita Wolfer Ulrich-Peter Rohr Source Type: research